文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

靶向治疗暴露-反应分析中的时间依赖偏倚与预后混杂:转移性肾癌舒尼替尼的启示

Time-Dependent Bias and Prognostic Confounding in Exposure-Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer.
PubMed 文献 · Clin Pharmacol Ther · 2026-08-12

该研究重新评估了舒尼替尼在转移性肾细胞癌中的暴露-反应关系,发现既往报道的正向关联主要由时间依赖偏倚和基线混杂因素(白蛋白、年龄)所致。校正混杂后高暴露与疗效无关,但仍与耐受性差相关,不支持基于总血浆浓度的暴露导向剂量递增。

要点

  • 舒尼替尼暴露-反应分析需警惕时间依赖偏倚和基线混杂。
  • 校正白蛋白和年龄后,高暴露与TTP/OS改善的关联消失。
  • 高暴露仍与剂量减少和因不良事件停药风险增加相关。

核心结论

  • 既往报道的舒尼替尼正向暴露-反应关系主要由时间依赖偏倚和混杂因素导致,不支持基于总血浆浓度的暴露导向剂量递增,而建议用治疗药物监测识别高暴露和毒性风险患者。

研究设计与样本

  • 基于四项临床试验共294例患者的人群药代动力学分析,并在165例细胞因子难治性患者中开展暴露-反应分析。

主要发现

  • 舒尼替尼和SU12662的表观清除率存在时间依赖性下降。
  • 采用早期基线锚定的暴露指标而非时间平均表观清除率时,高暴露与TTP和OS改善的正向关联减弱。
  • 校正白蛋白和年龄后,高暴露与TTP和OS的关联不再明显。
  • 将混杂因素固定于队列中位数进行模拟,各暴露组的TTP和OS曲线重叠。
  • 高暴露仍与耐受性差相关,包括剂量减少和因不良事件停药风险增加。

临床怎么用

  • 临床不应基于总血浆浓度进行暴露导向的剂量递增。
  • 可考虑采用治疗药物监测识别存在过度暴露和毒性风险的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Exposure-response (E-R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration-guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post-baseline dose modifications, time-varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical outcomes. We re-evaluated the E-R relationship of sunitinib in mRCC with explicit assessment of these biases. A population pharmacokinetic analysis of 294 patients from four clinical trials identified time-dependent declines in apparent clearance for sunitinib and SU12662. E-R analyses were performed in 165 cytokine-refractory patients treated with the approved 50 mg 4-weeks-on/2-weeks-off regimen, using time to progression (TTP), overall survival (OS), and tolerability-related outcomes. Baseline albumin and age were identified as shared covariates of exposure and outcome and incorporated as confounders in multivariable multistate survival models. The apparent positive association between higher exposure and improved TTP and OS was attenuated when exposure was defined using early, baseline-anchored metrics rather than time-averaged apparent clearance. It was no longer evident after adjustment for albumin and age. Consistently, simulations with confounders fixed at cohort medians showed overlapping TTP and OS profiles across exposure groups. In contrast, higher exposure remained associated with poorer tolerability, including increased risks of dose reduction and treatment discontinuation driven by adverse-events. These findings indicate that previously reported positive E-R relationships for sunitinib were largely due to time-dependent bias and confounding. The results do not support exposure-guided dose escalation based on total plasma concentrations, but instead suggest the use of therapeutic drug monitoring to identify patients at risk of excessive exposure and toxicity.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Liu H, Friberg LE. Time-Dependent Bias and Prognostic Confounding in Exposure-Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer. Clin Pharmacol Ther. 2026. PMID: 42587360. doi:10.1002/cpt.70447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。